Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
ARIPiprazole
ARIPiprazole
Brand names: Abilify, Abilify Discmelt, Aristada, Maintena
| Form | Strength |
|---|---|
| SOLUTION, INTRAMUSCULAR | 9.75 mg/1.3 mL |
| SOLUTION, ORAL | 1 mg/mL |
| SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR | ARIPiprazole (Maintena) 300 mg, 400 mg; ARIPiprazole lauroxil (Aristada) 441 mg, 662 mg, 882 mg, 1064 mg; Aristada Initio 675 mg |
| TABLET, DISINTEGRATING, ORAL | 10 mg |
| TABLET, ORAL | 2 mg; 5 mg; 10 mg; 15 mg; 20 mg; 30 mg |
Last updated: Apr. 17, 2023
- Black Box Warning: Elderly patients with dementia related psychosis
Aripiprazole
ARIPiprazole lauroxil (Aristada) long acting intramuscular injection is Formulary, Restricted to
• Established tolerability and efficacy of oral aripiprazole
• Confirmed eligibility for ongoing outpatient RX coverage. (ensure pt will continue to have access to the injections upon discharge, before treatment initiation)
• The site is participating in the HIFT free trial injection program (2 free per calendar year). The patient is eligible for the HIFT program and/or for Unity patients only with Care
Oregon coverage, additional doses may be available for reimbursement.
• For hospitalized and ED patients not eligible for the free trial, plan to continue oral supplementation with plans for resuming long acting injections (LAIs) upon outpatient
discharge
• Loading doses should not be utilized until 7 days+/-3 days to discharge date for those patients admitted for behavioral health stabilization. (patients with potential for
extended length of stay should continue to utilize oral bridge therapy until discharge plans are in place, then give loading doses of LAI)
See instructions on administration of ARIPiprazole lauroxil (Aristada) Long Acting Injectable - HERE